Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for Treatment of Acromegaly


Crinetics hosts a virtual Key Opinion Leader (KOL) meeting on oral paltusotine for the treatment of acromegaly on Friday, November 20, 2020 at 11:00 am Eastern Time. Peter Trainer, MD and Monica Roberto Gadelha, MD, PhD discuss implications of Phase 2 ACROBAT studies with oral paltusotine.

Third Quarter 2020 Financial Results and Corporate Update


Positive topline results for Phase 2 trials of oral paltusotine (acromegaly), CRN04777 received Rare Pediatric Disease Designation (congenital hyperinsulinism)

ACROBAT Edge Study of Paltusotine in Acromegaly Met Endpoint


Crinetics announces Paltusotine (for treatment of acromegaly) was observed to be safe and well-tolerated among the 60 participants in the ACROBAT Edge and ACROBAT Evolve Studies.

Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism


FDA grants rare pediatric disease designation: CRN04777 - investigational, orally available, SST5 agonist developing as treatment for congenital hyperinsulinism.

New Data from Paltusotine and ACTH Antagonist Development Programs- European Congress of Endocrinology


A presentation on the company’s orally administered, small molecule adrenocorticotropic hormone (ACTH) antagonist was selected for a late-breaking session at the virtual European Congress of Endocrinology (eECE) on September 8, 2020.